| __timestamp | Arrowhead Pharmaceuticals, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 54170000 |
| Thursday, January 1, 2015 | 34718089 | 65378000 |
| Friday, January 1, 2016 | 40998209 | 52263000 |
| Sunday, January 1, 2017 | 32022880 | 35072000 |
| Monday, January 1, 2018 | 19110051 | 27415000 |
| Tuesday, January 1, 2019 | 26556257 | 36983000 |
| Wednesday, January 1, 2020 | 52275890 | 50918000 |
| Friday, January 1, 2021 | 80981000 | 63586000 |
| Saturday, January 1, 2022 | 124431000 | 57967000 |
| Sunday, January 1, 2023 | 90932000 | 53107000 |
| Monday, January 1, 2024 | 98761000 | 23626000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, operational efficiency is key. Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2024, Arrowhead's SG&A expenses surged by approximately 300%, peaking in 2022. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Mesoblast's expenses have fluctuated, with a notable decline of around 64% from 2015 to 2024, indicating a strategic shift towards cost optimization. The year 2022 marked a pivotal point where Arrowhead's expenses were more than double those of Mesoblast, highlighting their divergent paths. As the biotech landscape evolves, these trends offer insights into each company's strategic priorities and market positioning.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Arrowhead Pharmaceuticals, Inc.
Viatris Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. vs Mesoblast Limited: SG&A Expense Trends
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Mesoblast Limited
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Corcept Therapeutics Incorporated vs Arrowhead Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Mesoblast Limited
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Arrowhead Pharmaceuticals, Inc.
Research and Development Investment: Arrowhead Pharmaceuticals, Inc. vs Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Mesoblast Limited
Mesoblast Limited or Xencor, Inc.: Who Manages SG&A Costs Better?